Latest Europe News

Little Green Pharma reported a robust September quarter with revenue exceeding $10 million, driven by growth across all product lines and strong European market performance. The company is poised to benefit from upcoming regulatory reforms and operational efficiencies.

Sprintex Limited has transitioned from development to commercial execution, securing major contracts in Europe, China, and India while raising A$1.5m to fund expansion.

Activeport Group Ltd reported steady Q1 FY26 results with key project deliveries and a successful capital raise, positioning the company for accelerated growth across Asia and beyond.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for chronic wound treatment and advances regulatory filings for its TR Pro+® product, while gearing up for a major commercial rollout in early 2026.

Ark Mines secured a $4.5 million strategic investment from QIC to fast-track its Sandy Mitchell Rare Earth Project, achieving key drilling and environmental milestones that pave the way for production by late 2027.

Harvest Technology Group reported improved EBITDA and secured new customers across mining, defence, and border control sectors in Q1 FY2026, supported by $2.13 million raised through convertible notes and loans.

Smart Parking Limited reports a record FY25 with revenues up 42% to $77.2 million, driven by organic growth and strategic acquisitions including Peak Parking in the US. The company targets 3,000 managed sites by 2028, leveraging proprietary AI technology across multiple international markets.

Ionic Rare Earths advances its global rare earths strategy with significant UK government funding, increased heavy rare earth oxide production, and a $15.6 million capital raise backed by a strategic US investor.

Amplia Therapeutics reports encouraging interim results for narmafotinib in metastatic pancreatic cancer, alongside a successful capital raise and key patent allowance.

Adslot Ltd reports solid progress in Q1 FY26, highlighting growth in its StoreFront and Marketplace platforms alongside a successful $989,000 capital raise to fuel expansion.

Dimerix Limited reports solid progress in its Phase 3 trial for DMX-200 targeting rare kidney disease FSGS, backed by orphan drug status in Japan and a robust cash position. The company prepares to engage the FDA on new data supporting regulatory approval.

Sarytogan Graphite Limited has secured major engineering contracts for its Definitive Feasibility Study, setting the stage for construction in 2027. The project’s strategic importance under the EU Critical Raw Materials Act highlights its role in the battery minerals supply chain.